Clinical Trial: Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: LH, FHS, Estradiol and Progesterone Activity During the 7-Day Hormone-Free Interval of Various Combined Oral Contraceptive Regimens
Brief Summary: The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol in the formulation. This variation in activation may be associated with different side effects during the hormone free interval. Progesterone (P) remained suppressed during all 6 COC regimens (<1.8 ng/mL), which indicates continuous contraceptive efficacy during the 7-day hormone free interval of all formulations studied.
Detailed Summary:
Sponsor: University of Southern California
Current Primary Outcome: follicle-stimulating hormone [ Time Frame: Serum blood samples were collected for hormone measurements at the same time daily during the 7 day hormone free interval ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- lutenizing hormone [ Time Frame: daily serum during the hormone free interval ]
- estradiol [ Time Frame: daily serum samples during the hormone free interval ]
- progesterone [ Time Frame: daily serum during the 7 day hormone free interval ]
Original Secondary Outcome: Same as current
Information By: University of Southern California
Dates:
Date Received: September 17, 2013
Date Started:
Date Completion:
Last Updated: September 25, 2013
Last Verified: September 2013
